Swissmedic said the United States pharmaceutical company Pfizer submitted an application for the authorisation of a vaccine which is based on the mRNA technology last week.
The agency added it is fast-tracking all applications connected with the Covid-19 pandemic, assigning extra staff to this task so that content checks and, in particular, user safety are not compromised.
The criteria for reviewing safety, efficacy and quality remain unchanged, according to Claus Bolte, head of Swissmedic’s authorisation division.
“The data packages for the vaccine candidates will be reviewed just as comprehensively, but faster. As a result, we can shorten the waiting times between the development stages during the review,” Bolte said in a statementExternal link published on Monday.
Two weeks ago, the Swiss authorities started assessing an application for a vaccine developed by the British-Swedish company AstraZeneca and Oxford University.
Switzerland has also signed a deal with US biotech firm Moderna to secure early access to 4.5 million doses of its Covid-19 vaccine.
Switzerland abstains from vote on Palestinian bid for full UN membership
This content was published on
On Friday, Switzerland abstained from the vote at the General Assembly on granting the Palestinians new rights at the United Nations (UN).
Protein in abdominal fat could help shape obesity treatment
This content was published on
The study analysed fat cells from different locations in the body, and found that those in the abdomen have unique properties.
North African asylum claims fall after rapid Swiss processing
This content was published on
The accelerated procedure, now out of its test phase, has resulted in a significant drop in applications from North African countries.
This content was published on
The artist's song "The Code" focuses on their journey as a nonbinary individual. It is one of the favourites to win this year's contest.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Covid cure further away than hoped, says Novartis chief
This content was published on
Swiss pharmaceutical firm Novartis has rowed back on earlier predictions that a drug to combat coronavirus could be on the horizon.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.